NCT01506336

Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib

A Prospective, Multicenter, Randomized, Open-label, Active Controlled, 2-parallel Group, Phase II Study to Compare Efficacy and Safety of Masitinib at 12 mg/kg/Day to Sunitinib at 50 mg/Day in Treatment of Patients With Gastro-intestinal Stromal Tumor Resistant to Imatinib

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 44 (actual)
• Sponsor: AB Science · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The objective is to compare efficacy and safety of masitinib at 12 mg/kg/day to sunitinib at 50 mg/day in treatment of patients with gastro-intestinal stromal tumor resistant to imatinib.

Conditions

• Gastro Intestinal Stromal Tumor

Interventions

Type	Name	Description
DRUG	masitinib	masitinib 12 mg/kg/day
DRUG	sunitinib	sunitinib 50 mg/day

Timeline

• Start date: 2008-10-01
• Primary completion: 2011-09-01
• Completion: 2012-04-01
• First posted: 2012-01-10
• Last updated: 2018-12-11

Locations

1 site across 1 country: France